CD3E and neoplasm: Considering that the anti-CD20 × CD3ε 2:1 TCB format appears to be more potent than various 1:1 anti-CD20 × CD3ε formats [160], it might be interesting to see how other multiple-tumor-target-binding × single CD3ε binding formats might behave.